In Q2, 2018, ISR asked 48 outsourcers of biologic API to select from four different reasons that manufacturing is split between in-house and external resources. The data below show how respondents rated their organization’s experience and capacity with respect to outsourcing large molecule drug substance, with the majority (48%) stating their company has adequate experience but lacks manufacturing capacity. To learn more, follow the link to the Development and Commercial Manufacturing Outsourcing Models report preview.

View File